Abstract:e19523 Background: Primary intestinal non-Hodgkin lymphoma (NHL) is a rare but heterogeneous disease in East Asia. However, the benefit of multidisciplinary treatment is still in debate. We characterized the clinicopathologic features, and treatment outcome in a single institute database. Methods: Patients with NHL primarily involving the intestine and treated during 1992 to 2008 were selected from the Cancer Registry of National Taiwan University Hospital. The medical charts and pathology records were carefully reviewed. Results: There were 64 men and 17 women with a median age of 51.5 years. Sites involved were colon/rectum (53.2%), small intestine (30.9%), and duodenum (13%). Histopathology subclassification included diffuse large B-cell lymphoma (DLBCL) (61.7%), mucosa-associated lymphoid tissue lymphoma (11.1%), Burkitt’s lymphoma (8.6%), T cell lymphoma (6.2%), follicular lymphoma (2.5%), mantle cell lymphoma (1.2 %) and others (8.6%). Ann Arbor stage IE to IIE accounted for 61.7%, whereas lower IPI score (1-2) were 54.8%. Among them, 27 patients received surgery plus chemotherapy, 60 received chemotherapy, and 4 had radiotherapy. At average follow-up of 48.7 months, 5 year survival rate were 59%, 43% and 51% for colon/rectum, small intestine, and duodenal NHL, respectively (p=0.45). Surgery plus chemotherapy versus chemotherapy alone showed no survival benefit in lower IPI group (p=0.682) nor in higher IPI (3-5) group (p=0.939). A trend of better median overall survival (mOS) was seen in rituximab group than in non-rituximab group in DLBCL subtypes (not reach vs. 39.8mo, p=0.075). In univariate analysis, stage III/IV (p=0.008), IPI score greater than 2 (p=0.011), and T cell histology (p<0.001) were significant prognostic factors for poor OS. In multivariate analysis, T cell histology remained the independent prognostic factor for inferior OS (p<0.001, HR: 20.3, 95% CI: 5.1-80.4). Conclusions: Although B cell NHL was the majority of primary intestinal NHL in our institute, T cell histology has significant inferior survival. Chemotherapy is still the backbone of treatment for primary intestinal NHL. The benefit of rituximab to intestinal DLBCL needs further confirmation.

PB2402: CLINICAL CHARACTERISTICSAND PROGNOSIS RISK FACTORS OF NON-HODGKIN’S LYMPHOMA INVOLVING THE HEART

Primary Cardiac Malignant Lymphoma: A Case Report And Literature Review

Significance of Clinical Factors As Prognostic Indicators for Mature T-Cell Non-Hodgkin Lymphoma Patients: A Retrospective Analysis of Chinese Cases

Pathological features and prognosis of natural killer cell lymphoma and leukemia

Clinicopathologic Features and Treatment Outcome of Primary Intestinal Non-Hodgkin Lymphoma: A Single Center Experience.

Primary testicular non-Hodgkin's lymphoma: clinical analysis of 21 cases]

Atypical location of primary cardiac lymphoma in the left heart with atypical clinical presentation: A case report and literature review

Relapsed/refractory diffuse large B cell lymphoma with cardiac involvement: A case report and literature review

[Clinical Study of P-gp, and Bcl-2 Protein Expression in Non-Hodgkin's Lymphomas Patients].

Significance of Clinical Factors As Prognostic Indicators for Patients with Peripheral T-cell Non-Hodgkin Lymphoma: A Retrospective Analysis of 252 Cases

[Clinical Analysis of Liver Non-Hodgkin's Lymphoma].

Treatment outcome and prognosis in stage Ⅰ/Ⅱ primary non-Hodgkin lymphoma of the breast

Primary cardiac lymphoma: the management and outcome of a single-centre cohort of 22 patients

Analysis of the Clinicopathologic Characteristics and Prognosis of Head and Neck Lymphoma

CMAR_A_243672 3155..3162

Retrospective analysis of 91 patients with T cell non-Hodgkin's lymphoma

Clinical Analysis of Primary Non-Hodgkin′s Lymphoma of Breast

Clinical features analysis on primary central nervous system lymphoma

Primary Laryngeal Non-Hodgkin Lymphoma:a Clinical Analysis of 24 Cases

Analysis of the Characteristics of Cardiovascular Diseases Affecting the Survival of Patients with Lymphoma

Primary Non-Hodgkin’s Lymphoma of the Breast: Eight-Year Follow-Up Experience